middle.news
Tryptamine Therapeutics Advances Psilocin Trials, Raises $6M to Fuel Growth
9:21am on Thursday 30th of January, 2025 AEDT
•
Biotechnology
Read Story
Tryptamine Therapeutics Advances Psilocin Trials, Raises $6M to Fuel Growth
9:21am on Thursday 30th of January, 2025 AEDT
Key Points
Phase 1b trial confirms safety and optimal dosing of TRP-8803 in healthy and obese volunteers
Positive interim Phase 2a results for TRP-8802 in IBS patients with 75% reporting symptom relief
Successful $6 million capital raise led by strategic biotech investors
Board changes include appointment of Dr Daniel Tillett as Non-Executive Director
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
TYP
OPEN ARTICLE